Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity. Technology Overview: Prostate cancer is the most common non-cutaneous malignancy, and the second leading cause of cancer-related death in men of the western world....